Peripartum Cardiomyopathy

• Hormonal hypothesis: Pregnancy is associated with physiologic increases in estrogen, prolactin, and other hormones. The catabolism of prolactin by matrix metalloproteinase-2 (MMP-2) produces a 16-kDa N-terminal prolactin fragment with potent anti-angiogenic and pro-apoptotic properties. This cleaved prolactin impairs cardiac myocyte function, increases oxidative stress, and promotes apoptosis. Elevated prolactin levels in the peripartum period may exacerbate these effects.

• Myocarditis and immune activation: Gestational immune tolerance ends abruptly at parturition, with marked shifts in Th1/Th2 cytokine balance. Increased expression of inflammatory cytokines (TNF-α, IL-6, IL-1β) and activation of autoimmune pathways targeting cardiac myosin and other cardiac antigens have been documented. Some cases demonstrate evidence of lymphocytic myocarditis on endomyocardial biopsy, suggesting viral and/or autoimmune triggering.

• Hemodynamic stress: Pregnancy induces profound alterations in cardiac physiology including increased blood volume (30-50%), increased heart rate, decreased systemic vascular resistance, and increased cardiac output. The physiologic compensatory mechanisms (eccentric hypertrophy, increased contractility) may become maladaptive in susceptible individuals, particularly in the abrupt hemodynamic changes postpartum when blood volume rapidly contracts.

• Oxidative stress and endothelial dysfunction: Increased oxidative stress in pregnancy, exacerbated by abnormal angiogenesis and deficient endothelial function, impairs nitric oxide (NO) availability and promotes endothelial dysfunction. Impaired placental development and preeclampsia predispose to these mechanisms.

• Vascular endothelial growth factor (VEGF) deficiency: Abnormal angiogenesis with reduced VEGF signaling in peripartum women predisposes to myocardial ischemia and cardiomyocyte dysfunction.

• Genetic predisposition: Several genetic variants associated with dilated cardiomyopathy (TTN, LMNA, BAG3) have been identified in PPCM cohorts, suggesting genetic susceptibility in combination with peripartum triggers.

Established Risk Factors

• Advanced maternal age (>30 years)
• Multiparity (increasing parity increases risk)
• African descent (2-10 fold increased risk)
• Multiple gestations (twin or higher order pregnancies)
• Preeclampsia/eclampsia
• Gestational hypertension
• Postpartum transfusion
• Prolonged labor or emergency cesarean section
• Obesity
• Smoking
• Cocaine use
• Anemia during pregnancy

Associated Conditions/Triggers

• Viral infections (peripartum viral myocarditis, particularly enteroviruses)
• Autoimmune diseases (systemic lupus erythematosus, other connective tissue disorders)
• Prior cardiomyopathy or heart disease
• Familial dilated cardiomyopathy
• Uncontrolled hypertension during pregnancy

Timing and Cardinal Features

• Onset: Typically 2-4 weeks postpartum (>90% of cases), though can occur in last trimester or up to 5 months postpartum
• Dyspnea: Progressive dyspnea on exertion, orthopnea, or paroxysmal nocturnal dyspnea (most common presenting symptom)
• Fatigue and weakness: Often attributed to postpartum status, delaying diagnosis
• Chest discomfort or palpitations
• Syncope or presyncope (particularly with arrhythmias)

Physical Examination Findings

• Tachycardia (resting heart rate >100 bpm)
• Tachypnea (respiratory rate >20)
• Elevated jugular venous pressure (JVP)
• Displaced apical impulse (laterally and inferiorly)
• S3 gallop (ventricular gallop, hallmark finding)
• S4 gallop (atrial gallop, may occur with diastolic dysfunction)
• Pulmonary crackles/rales at lung bases
• Lower extremity edema and ascites (in advanced cases)
• Hepatomegaly and hepatic tenderness (hepatic congestion)
• Cool extremities (low cardiac output state)
• Hypotension (in severe/cardiogenic shock cases)
• Pulmonary edema (acute respiratory distress)

Variable Presentations

• Some patients present in acute cardiogenic shock with hemodynamic compromise
• Others present with subclinical/mild dysfunction discovered incidentally during workup for dyspnea
• Arrhythmias (supraventricular and ventricular) may be presenting feature
• Thromboembolic phenomena may present with stroke, pulmonary embolism, or systemic embolization

Clinical Suspicion

Diagnostic Tests

Electrocardiography (ECG)

• Nonspecific ST segment and T wave changes
• Left ventricular hypertrophy (LVH) voltage criteria
• Left axis deviation
• Atrial or ventricular arrhythmias (atrial fibrillation common)
• Conduction abnormalities (LBBB, prolonged QT)
• Not diagnostic but supports heart failure etiology

Natriuretic Peptides

• B-type natriuretic peptide (BNP): Markedly elevated (often >400 pg/mL, frequently >1000 pg/mL)
• N-terminal pro-BNP (NT-proBNP): Markedly elevated
• Excellent negative predictive value; normal BNP makes PPCM unlikely
• Serial measurements track clinical response to therapy

Laboratory Studies

• Troponin I/T: Elevated in 30-40% of cases (suggests myocarditis component); not diagnostic
• Complete blood count (CBC): Anemia common; evaluate for contributory factors
• Comprehensive metabolic panel (CMP): Assess renal function (prognostic), electrolytes, thyroid function
• Thyroid-stimulating hormone (TSH) and free T4: Rule out peripartum thyroiditis and thyroid dysfunction
• Viral serologies: May support myocarditis hypothesis (enterovirus, parvovirus B19, CMV, EBV)
• Autoantibodies: Anti-cardiac myosin, anti-troponin may be positive
• Prothrombin time (PT)/INR, activated partial thromboplastin time (aPTT): Baseline assessment for anticoagulation

Chest Radiography

• Cardiomegaly (enlarged cardiac silhouette with cardiothoracic ratio >0.5)
• Pulmonary edema (bilateral interstitial or alveolar infiltrates in perihilar distribution)
• Pulmonary vascular congestion (cephalization of pulmonary vessels)
• Pleural effusions (usually bilateral, often right > left)
• Interstitial edema with Kerley B lines

Transthoracic Echocardiography (TTE) - GOLD STANDARD

• Left ventricular ejection fraction (LVEF): ≤45% (diagnostic requirement); typically severely reduced (20-35%)
• Left ventricular dilatation: LV end-diastolic dimension >55 mm (or indexed >32 mm/m²)
• Global hypokinesis: Reduced shortening fraction and strain imaging
• Reduced cardiac output: Decreased stroke volume
• Elevated filling pressures: Restrictive or pseudonormal diastolic dysfunction pattern
• Elevated E/e' ratio on tissue Doppler imaging
• Reduced left ventricular global longitudinal strain (GLS)
• Secondary mitral regurgitation (functional, from papillary muscle displacement)
• Secondary tricuspid regurgitation
• Right ventricular dilatation and dysfunction (in advanced cases)
• Reduced right ventricular systolic excursion (RVSE)
• Thrombus formation: Screen for LV apical thrombus (present in ~5-10%, risk with severe dysfunction)
• Pericardial effusion: May be present (supports myocarditis hypothesis if absent tamponade)

Advanced Imaging

Cardiac MRI

• Indications: Diagnosis uncertain, atypical presentation, suspected myocarditis, risk stratification
• T1 and T2 mapping: Native T1 elevation suggests edema; post-contrast T1 changes indicate fibrosis
• Late gadolinium enhancement (LGE): Mid-wall fibrosis pattern in myocarditis; subepicardial or patchy enhancement may indicate myocardial inflammation
• Strain imaging: Reduced global longitudinal strain
• Tissue characterization helps differentiate PPCM from other cardiomyopathies

Endomyocardial Biopsy

• Not routinely performed (invasive with limited therapeutic implications)
• Consideration: Persistent hemodynamic deterioration despite optimal therapy, suspected fulminant myocarditis, need for definitive tissue diagnosis
• Findings if performed: Lymphocytic infiltration (myocarditis), myocyte hypertrophy, interstitial fibrosis, necrosis

Diagnostic Criteria for PPCM (Modified Johns Hopkins)

1. 1.Onset of congestive heart failure symptoms in the last month of pregnancy or within 5 months postpartum
2. 2.Absence of identifiable alternative cause of heart failure
3. 3.Systolic dysfunction with LVEF <45% or fractional shortening <30% on echocardiography
4. 4.Elevated natriuretic peptide levels (supporting criterion, though not mandatory if LVEF severely reduced)

Acute Stabilization (Severe Presentation/Cardiogenic Shock)

• Oxygen supplementation: Target SpO₂ >90-94%; consider non-invasive ventilation (CPAP/BiPAP) or intubation if respiratory distress
• Intravenous diuretics: Furosemide 40-80 mg IV with titration for pulmonary edema; monitor urine output, electrolytes, renal function
• Vasodilators (IV nitroglycerin or nitroprusside): Reduce afterload in hypertensive patients with pulmonary edema
• Inotropic support (if hypotensive/low output): Dobutamine or milrinone for cardiogenic shock; avoid tachycardia induction
• Mechanical circulatory support: Consider intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) for refractory shock or as bridge to recovery/transplantation
• Continuous hemodynamic monitoring: Pulmonary artery catheter for refractory cases to guide therapy
• Anticoagulation: Unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) bridging to warfarin for LV thrombus, atrial fibrillation, or severe dysfunction (LVEF <25%)

Chronic Management (ACEI/ARB + Beta-Blockers + Diuretics)

ACE Inhibitors or Angiotensin Receptor Blockers (First-Line)

• Lisinopril 5-10 mg daily OR Enalapril 5 mg twice daily OR Ramipril 2.5-5 mg daily (typical ACEI agents)
• Losartan 50 mg daily OR Valsartan 80-160 mg daily (typical ARB agents)
• Mechanism: Inhibit angiotensin II, reduce vasoconstriction, decrease sympathetic activation, promote vasodilation, reduce cardiac remodeling
• Target dose: Titrate to maximally tolerated dose as tolerated
• Monitoring: Check baseline and follow-up renal function, potassium; expect small rise in creatinine (≤30% acceptable)
• Contraindications: Hypotension (SBP <90 mmHg), hyperkalemia (K >5.5), severe renal dysfunction

Beta-Blockers (First-Line)

• Carvedilol 3.125 mg daily, titrating to 6.25-25 mg daily (preferred due to alpha-blocking properties and antioxidant effects)
• Metoprolol succinate (extended-release) 25-190 mg daily (use succinate formulation, not tartrate)
• Bisoprolol 1.25-10 mg daily
• Mechanism: Reduce sympathetic tone, decrease heart rate, improve diastolic filling, reduce myocardial oxygen demand, promote reverse remodeling
• Start low, go slow: Begin at lowest dose; titrate every 2-4 weeks as tolerated
• Contraindications: Decompensated heart failure, cardiogenic shock (may require inotropes first), bradycardia <50 bpm, hypotension
• Interaction with breastfeeding: Most beta-blockers safe; limited excretion into breast milk

Diuretics (Symptom Management)

• Loop diuretics: Furosemide 20-40 mg daily or Torsemide 10-20 mg daily (longer half-life)
• Thiazide diuretics: Hydrochlorothiazide 12.5-25 mg daily (for mild volume overload; avoid if severe dysfunction)
• Potassium-sparing diuretics: Spironolactone 12.5-50 mg daily (aldosterone antagonist; see below)
• Mechanism: Reduce preload, relieve congestion symptoms
• Target: Euvolemia (no orthopnea, PND, edema)
• Monitoring: Electrolytes, renal function; adjust based on volume status

Aldosterone Antagonist (Evidence-Based)

• Spironolactone 12.5-50 mg daily (preferred) OR Eplerenone 25-50 mg daily
• Indication: Reduce mortality in systolic heart failure; particularly beneficial in PPCM given inflammatory pathophysiology
• Mechanism: Block aldosterone effects, reduce cardiac remodeling, reduce fibrosis, anti-inflammatory
• Monitoring: Potassium (target <5.5), creatinine; contraindicated if K >5.5 or Cr >2.5
• Caution: Triple therapy (ACEI + beta-blocker + spironolactone) requires careful monitoring

Disease-related complications

• Cardiogenic shock and refractory pulmonary edema (emergency): abrupt loss of stroke volume in an already volume-loaded peripartum circulation. Signaled by hypotension, narrow pulse pressure, cool mottled extremities, rising lactate, and oliguria. The 2022 AHA/ACC/HFSA Heart Failure Guideline supports early transfer to a center capable of temporary mechanical circulatory support (IABP, ECMO) and durable LVAD or transplant evaluation when shock persists.
• Ventricular arrhythmias and sudden cardiac death (emergency): fibrosis, inflammation, and neurohormonal activation create reentrant substrate. Watch for syncope, wide-complex tachycardia, and the shockable pair ventricular fibrillation / pulseless VT, which mandates immediate defibrillation. Atrial fibrillation may precipitate decompensation by loss of atrial kick.
• Thromboembolism (emergency when it embolizes): pregnancy is a hypercoagulable state, and a dilated akinetic ventricle adds stasis — the highest thrombotic risk of any cardiomyopathy. Presents as LV apical thrombus on echo, stroke, limb ischemia, or PE.
• Persistent LV dysfunction and recurrence: failure to normalize EF predicts relapse with a subsequent pregnancy; women with unrecovered EF are counseled against future pregnancy per ACOG and AHA pregnancy-cardiovascular guidance.

Treatment-related complications

• ACEI/ARB/ARNI and MRA fetal toxicity: contraindicated antepartum — RAAS blockade causes fetal renal hypoperfusion, oligohydramnios, and skull hypoplasia. These agents (plus SGLT2 inhibitors) belong to the postpartum regimen; hydralazine–nitrate plus a beta blocker is the antepartum substitute.
• Overdiuresis: reduces uteroplacental perfusion antepartum and causes prerenal AKI, hyponatremia, and hypokalemia.
• Hyperkalemia/AKI from combined RAAS and MRA therapy — check potassium and creatinine after each titration.
• Anticoagulation: bleeding, and warfarin embryopathy in the first trimester, so LMWH is preferred antepartum.
• Bromocriptine: thrombotic and ischemic events; it should never be given without concurrent anticoagulation, and it suppresses lactation.
• Premature ICD implantation: because recovery is common, guidelines favor a wearable cardioverter-defibrillator during the initial months of guideline-directed therapy before committing to a device.

• **The stem is a woman 2–4 weeks postpartum with dyspnea, orthopnea, and an *S3 gallop***: fatigue and edema get dismissed as normal postpartum findings, which is exactly the trap. Any peripartum patient with orthopnea or PND deserves a cardiac workup.
• Single best next step is transthoracic echocardiography. BNP/NT-proBNP is a useful screen (a normal value makes PPCM very unlikely), but the diagnosis requires demonstrating LVEF ≤45% with no alternative cause.
• **The mechanism examiners test is the *16-kDa prolactin fragment* generated by cathepsin D/MMP cleavage of prolactin — anti-angiogenic and pro-apoptotic. This is the rationale for bromocriptine**, a dopamine D2 agonist that suppresses prolactin; it is investigational in the US and must be paired with anticoagulation because it is prothrombotic.
• Antepartum vs postpartum pharmacology is the classic drug question. ACE inhibitors, ARBs, ARNI, MRAs, and SGLT2 inhibitors are avoided during pregnancy; captopril's short half-life makes it useful for rapid titration outside pregnancy, not safe within it. Antepartum: hydralazine plus nitrate, a beta blocker, and cautious loop diuresis. Once delivered and not breastfeeding-limited, escalate to the full four-pillar HFrEF regimen endorsed by the 2022 AHA/ACC/HFSA guideline — ARNI (or ACEI/ARB), beta blocker, MRA, and SGLT2 inhibitor.
• Anticoagulate the very low EF. Peripartum hypercoagulability plus LV stasis makes apical thrombus and stroke disproportionately common; LMWH antepartum, warfarin acceptable postpartum.
• Recovery is the distinguishing feature: roughly half normalize LV function, so defer permanent ICD placement and use a wearable defibrillator during the recovery window.
• Counseling association: failure to recover EF predicts relapse and maternal death with a subsequent pregnancy.
• Common distractors: amniotic fluid embolism, pulmonary embolism, preeclampsia with pulmonary edema, and severe anemia — all cause peripartum dyspnea, but none produce a dilated, globally hypokinetic ventricle on echo.